U.S. Markets open in 6 hrs 54 mins

Roche Holding AG (RHHBF)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
263.53-0.52 (-0.20%)
At close: 1:21PM EDT
People also watch
RHHVFRHHBYNSRGFSNYNFNVSEF
Full screen
Previous Close264.05
Open0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume120
Market Cap214.56B
BetaN/A
PE Ratio (TTM)23.03
EPS (TTM)11.44
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks2 days ago

    Roche's (RHHBY) Combination Cancer Remedy Wins FDA Approval

    Roche (RHHBY) announced that the FDA has granted approval to the subcutaneous injection of its marketed lymphoma drug MabThera/Rituxan as Rituxan Hycela for the treatment of adults with different types of blood cancers.

  • Reuters2 days ago

    New Roche haemophilia drug prevents bleeds but questions remain

    Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients with resistance to standard therapy compared with those who received another treatment, the Swiss company said on Monday. Roche is counting on emicizumab to wrest a share of the $11 billion-a-year haemophilia drug market now dominated by traditional treatments from Novo Nordisk and Shire . Some analysts called Monday's data release convincing, with Jefferies saying it underpinned its $5 billion peak sales estimate for the medicine.

  • Reuters2 days ago

    Roche says new haemophilia drug cuts bleed rate by 87 pct

    Roche's investigational haemophilia drug emicizumab cut the bleed rate by 87 percent in patients who had developed resistance to standard treatment, compared with those who instead got bypassing agents, the Swiss company said on Monday. Roche is counting on emicizumab to wrest a share of the $11 billion-a-year haemophilia drug market now dominated by traditional treatments from Novo Nordisk and Shire . In the late-stage study, 62.9 percent of patients receiving emicizumab experienced zero treated bleeds compared to 5.6 percent of those receiving so-called bypassing agents, Roche said.